skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Gender differences in clinical, immunological, and virological outcomes in highly active antiretroviral-treated HIV–HCV coinfected patients

Original Research

(1603) Views  (488) Full article downloads

Authors: Joel Emery, Neora Pick, Edward J Mills, et al

Published Date May 2010 Volume 2010:4 Pages 97 - 103
DOI: http://dx.doi.org/10.2147/PPA.S9949

Joel Emery1, Neora Pick2, Edward J Mills3, Curtis L Cooper1

1The Ottawa Hospital Division of Infectious Diseases, University of Ottawa, Ottawa, Canada; 2Oak Tree Clinic, BC Women’s Hospital, Vancouver, Canada; 3Faculty of Health Sciences, University of Ottawa, Ottawa, Canada

Objective: The influence of biological sex on human immunodeficiency virus (HIV) antiretroviral treatment outcome is not well described in HIV–hepatitis C (HCV) coinfection.

Methods: We assessed patients’ clinical outcomes of HIV–HCV coinfected patients initiating antiretroviral therapy attending the Ottawa Hospital Immunodeficiency Clinic from January 1996 to June 2008.

Results: We assessed 144 males and 39 females. Although similar in most baseline characteristics, the CD4 count was higher in females (375 vs 290 cells/μL). Fewer females initiated ritonavir-boosted regimens. The median duration on therapy before interruption or change was longer in males (10 versus 4 months) (odds ratio [OR] 1.40 95% confidence interval: 0.95–2.04; P = 0.09). HIV RNA suppression was frequent (74%) and mean CD4 count achieved robust (over 400 cells/μL) at 6 months, irrespective of sex. The primary reasons for therapy interruption in females and males included: gastrointestinal intolerance (25% vs 19%; P = 0.42); poor adherence (22% vs 15%; P = 0.31); neuropsychiatric symptoms (19% vs 5%; P = 0.003); and lost to follow-up (3% vs 13%; P = 0.08). Seven males (5%) and no females discontinued therapy for liver-specific complications. Death rate was higher in females (23% vs 7%; P = 0.003).

Conclusion: There are subtle differences in the characteristics of female and male HIV–HCV coinfected patients that influence HIV treatment decisions. The reasons for treatment interruption and change differ by biological sex. This knowledge should be considered when starting HIV therapy and in efforts to improve treatment outcomes.

Keywords: AIDS, HIV, HCV, coinfection, HAART, viral load, women, gender differences, outcome, CD4 cell counts






 

Other articles by Dr Curtis Cooper



Readers of this article also read:

Effectiveness, tolerability and safety of azithromycin 1% in DuraSite® for acute bacterial conjunctivitis
Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study
Primary care for diabetes mellitus: perspective from older patients
Impact of household food insecurity on the nutritional status and the response to therapeutic feeding of people living with human immunodeficiency virus
Incidence of adverse events with telmisartan compared with ACE inhibitors: evidence from a pooled analysis of clinical trials
Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden?
Impact of pharmacist interventions on patients' adherence to antidepressants and patient-reported outcomes: a systematic review
The impact of pharmacist face-to-face counseling to improve medication adherence among patients initiating statin therapy
Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma
Preprocedure patient preferences and attitudes toward permanent contraceptive options